CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 7 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,034,478 | -43.0% | 265,135 | -29.4% | 0.13% | -34.7% |
Q2 2023 | $21,096,738 | +906.4% | 375,788 | +710.8% | 0.20% | +818.2% |
Q1 2023 | $2,096,275 | -7.7% | 46,347 | -17.0% | 0.02% | -12.0% |
Q4 2022 | $2,271,156 | -89.1% | 55,871 | -82.5% | 0.02% | -89.8% |
Q3 2022 | $20,841,000 | +103.5% | 318,910 | +89.3% | 0.24% | +106.8% |
Q2 2022 | $10,239,000 | +10.3% | 168,485 | +13.9% | 0.12% | +40.5% |
Q1 2022 | $9,285,000 | +1802.7% | 147,917 | +4542.7% | 0.08% | +2000.0% |
Q4 2020 | $488,000 | +82.8% | 3,186 | -0.0% | 0.00% | +100.0% |
Q3 2020 | $267,000 | -97.7% | 3,187 | -98.0% | 0.00% | -98.1% |
Q2 2020 | $11,719,000 | +140.0% | 159,458 | +38.5% | 0.10% | +89.1% |
Q1 2020 | $4,882,000 | +4.6% | 115,112 | +50.2% | 0.06% | +61.8% |
Q4 2019 | $4,668,000 | +45.4% | 76,636 | +40.3% | 0.03% | +47.8% |
Q2 2018 | $3,210,000 | – | 54,631 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |